Profiel
David Green worked as an Executive Director of Clinical Operations at Amgen, Inc. from 1997 to 2008.
He also worked as an Executive Director at United Therapeutics Corp., a Clinical Program Manager at Abbott Laboratories, and a Vice President of Global Clinical Operations at both Aquinox Pharmaceuticals, Inc. and ReSearch Pharmaceutical Services, Inc.
Eerdere bekende functies van David Green
| Bedrijven | Functie | Einde |
|---|---|---|
| AMGEN INC. | Chief Tech/Sci/R&D Officer | 01-02-2008 |
| ABBOTT LABORATORIES | Corporate Officer/Principal | - |
| UNITED THERAPEUTICS CORPORATION | Director/Board Member | - |
| ReSearch Pharmaceutical Services, Inc. | Chief Tech/Sci/R&D Officer | - |
Aquinox Pharmaceuticals, Inc.
 Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | Chief Tech/Sci/R&D Officer | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| AMGEN INC. | Health Technology |
| UNITED THERAPEUTICS CORPORATION | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
| ReSearch Pharmaceutical Services, Inc. |
